<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02435732</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0195</org_study_id>
    <nct_id>NCT02435732</nct_id>
  </id_info>
  <brief_title>CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI&gt;85% Organs</brief_title>
  <official_title>A Phase I, Single Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Tolerability of C1 Inhibitor (CINRYZE) as a Donor Pre-treatment Strategy in Brain Dead Donors Who Meet a Kidney Donor Risk Index (KDRI) Above 85%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Limiting brain death-induced organ injury through a systemic anti- inflammatory medical
      management should allow for improvement in the quality of transplanted organs, and as a
      result, clinical improvement in post-transplant outcomes represented by a decrease in the
      incidence of delayed graft function (DGF) after transplantation.

      The specific aim is to evaluate the effect of C1INH (CINRYZE) as a donor pre-treatment
      strategy to decrease systemic inflammation and decrease the incidence of DGF in Expanded
      Criteria Donors (ECD), currently identified as donors with Kidney Donor Profile Index (KDPI)
      over 85%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, single-center double-blinded study.

      Donor Pre-treatment Strategy:

      The main objective is to identify the lowest dose that will allow an at least 80% decrease in
      the activity of classic pathway and Mannose-Binding Lectin (MBL) pathway of complement. The
      main objectives parallel observations in non-human primates in which animals receiving
      kidneys from donors in which activity of both classic and MBL pathways of complement were
      reduced by at least 50% with the use of C1 inhibitors displayed very mild or no delayed graft
      function after transplantation.

      This trial has specifically been designed to evaluate the beneficial effect of C1INH in
      kidneys with a high rate of delayed graft function (donors meeting the criteria for expanded
      criteria kidneys). The nomenclature of Expanded Criteria Donors (ECD) donors has now been
      replaced using the Kidney Donor Profile Index (KDPI). Kidneys with a KDPI over 85% are
      considered equivalent to the old nomenclature of ECD donors. The selection of potential
      donors to be part of this study will be limited to the population of donors with a KDPI over
      85%. Participation in each group will be randomly assigned. C1INH or vehicle treatment will
      be administered within 6 hours of brain death declaration.

      A total of 36 brain dead donors will be randomized into 3 groups:

      Group 1: Control group: standard donor management + vehicle treatment (n=12) Group 2:
      Standard donor management + C1INH at a dose of 200 U/Kg IV single dose (n=12) Group 3:
      Standard donor management + C1INH at a dose of 200 units/kg IV single dose and heparin at 20
      units/kg/h IV maintenance until organ recovery (n=12).

      (Heparin and other glycosaminoglycans have been shown to have a profound effect on the
      regulation of complement activity in vitro and in vivo when combined with C1INH. For that
      purpose, C1INH 200 units/kg of C1INH in combination with heparin will be used to potentially
      reduce the cost of intervention. Based on preliminary data obtained in animal models, heparin
      dosed at 20units/kg will be administered in combination with C1INH. This dose represents
      approximately 0.25 units/ml, which has been tested to minimally alter partial thromboplastin
      time when a combination of the two drugs is used. When both drugs were used in a preclinical
      model (pig), an increased and synergistic inhibition of the classic pathway (approximately
      50% greater) was observed when compared to animals in which the C1INH was used alone.)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lowest dose that will allow at least an 80% decrease in the activity of classic pathway and MBL pathway of complement in brain death donors with KDPI over 85%, with the purpose of reducing the incidence of delayed graft function.</measure>
    <time_frame>over a 12 month period</time_frame>
    <description>Assessment of graft function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Donor Pharmacokinetics: plasma concentrations and Area under the Curve (AUC) for CINRYZE</measure>
    <time_frame>At various timepoints within first 24 hours</time_frame>
    <description>pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of of DGF in kidney transplantation from ECD brain death donors</measure>
    <time_frame>Within 6 hours of brain death</time_frame>
    <description>DGF rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of suppression of the classical and MBL pathways</measure>
    <time_frame>Within 6 hours of brain death</time_frame>
    <description>classical and MBL pathways</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Day of Transplant: first 24 hours, days 2-7, weeks 2,3,8, month 3, 6, 12</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of complement activation after brain death in donors treated with C1INH</measure>
    <time_frame>Within 6 hours of brain death</time_frame>
    <description>complement activation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard donor management + vehicle treatment (n=9)- placebo saline solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CINRYZE 200 U/Kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention is CINRYZE 200 U/Kg IV single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 units/kg IV CINRYZE with Heparin 20 U/kg/h IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CINRYZE 200 units/kg IV single dose with Heparin at 20 units/kg/h IV maintenance until organ recovery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo saline solution</intervention_name>
    <description>saline solution</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>CINRYZE 200 U/Kg IV</arm_group_label>
    <arm_group_label>200 units/kg IV CINRYZE with Heparin 20 U/kg/h IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Added to the one of the arms receiving 200U/kg dose of CINRYZE</description>
    <arm_group_label>200 units/kg IV CINRYZE with Heparin 20 U/kg/h IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CINRYZE</intervention_name>
    <description>200U/kg IV dose with or without heparin, or 500U/kg IV dose</description>
    <arm_group_label>CINRYZE 200 U/Kg IV</arm_group_label>
    <arm_group_label>200 units/kg IV CINRYZE with Heparin 20 U/kg/h IV</arm_group_label>
    <other_name>C1INH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent.

          -  Accepted for renal transplantation due to end stage renal disease (Chronic Kidney
             Disease Stage V).

          -  Recipient of a first or second renal transplant.

          -  For second renal transplantations:

          -  Minimum 3 months since the loss of the first transplanted kidney.

          -  At least 18 years of age:

        If female, patient must be/have:

          -  Post-menopausal, defined as the absence of menses for at least one year (serum FSH
             â‰¥20I U/L can also be measured according to local practice), OR Surgically sterile,
             defined as a bilateral tubal ligation at least 6 months prior to administration of
             study drug, bilateral oophorectomy, or complete hysterectomy, OR Using an effective
             means of contraception (per Appendix 1) that is planned to continue for the duration
             of the study (one year), AND negative urine pregnancy test if the patient is capable
             of providing a urine sample. If not capable to provide urine sample, serological
             pregnancy test will be perform. Female patients of childbearing potential who are
             anuric must have a serum pregnancy test.

        If male, patient must:

          -  Agree to use an effective means of contraception (per site-specific guidelines) that
             is planned to continue for the duration of the study (one year).

          -  Agree not to donate sperm until 6 months after dosing.

        Willingness to comply with the protocol procedures for the duration of the study, including
        scheduled follow-up visits and examinations.

        Exclusion Criteria:

          -  Use of an investigational drug in the 30 days before surgery.

          -  Participation in any other research study (drug or non-drug) without prior approval
             from the Medical Monitor.

          -  Known hypersensitivity to human monoclonal antibodies or any of the study drug
             excipients.

          -  Previous hypersensitivity to basiliximab, Campath-1H or antithymocyte globulin (ATG)

          -  History of or known HIV, HBV (surface antigen), or HCV positivity

          -  History of malignancy within the last five years, except excised squamous or basal
             cell carcinoma of the skin, or cervical intraepithelial neoplasia.

          -  Scheduled to undergo multi-organ transplantation.

          -  Presence of clinically significant infections requiring continued therapy.

          -  Positive screening for active tuberculosis.

          -  Existence of any surgical or medical condition, other than the current transplantation
             which, in the opinion of the investigator, might significantly alter the distribution,
             metabolism or excretion of study medication.

          -  History or presence of a medical condition or disease that in the investigator's
             assessment would place the patient at an unacceptable risk for study participation.

          -  Lactating or pregnant woman.

          -  Patient institutionalized by administrative or court order.

          -  HLA or ABO incompatible kidney defined as a positive cytotoxic crossmatch or positive
             flow cross match.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Fernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin- department of Surgery-Transplantation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis Fernandez, MD</last_name>
    <phone>(608) 263-9903</phone>
    <email>luisf@surgery.wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Schneider Kristi, NPH</last_name>
    <phone>(608) 263-7064</phone>
    <email>schneide@surgery.wisc.edu</email>
  </overall_contact_backup>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2015</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

